Hochspezifische Biomarker-Liganden für Ihre Bedürfnisse
Individuelle Betreuung durch international renommierte Fachexperten
The future in therapy: we fight your cancer
Molecular Internal Radionuclide Therapy
Tailored & personalized therapy planning
Highly specific biomarker ligands to meet your demands
Individual care through internationally renowned experts
Il gruppo di lavoro diretto dal Prof. Markus Hartenbach è stato in grado di dimostrare la superiorità del PSMA PET nella diagnosi della recidiva biochimica del cancro della prostata, anche a bassi livelli di PSA.
Die Zukunft hat begonnen. Therapie auf dem nächsten Level.
The future has started. Experience therapy on the next level.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Therapie der Zukunft: we fight your cancer
